Image Place holder

Michael R. Shafique, MD


Specialty: Medical Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Dr. Shafique earned his MD degree at the University of Virginia, School of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center and, most recently, a Hematology and Oncology Fellowship at University of South Florida/Moffitt Cancer Center. Dr. Shafique devotes the majority of clinical time treating lung cancer. However, he will also cares for patients with a wide spectrum of diagnoses as part of early phase clinical trials.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of South Florida - Hematology and Oncology

Residency:

  • Duke University Medical Center - Internal Medicine

Medical School:

  • University of Virginia School of Medicine - MD
Participating Trials

CLINICAL TRIAL 19293
Phase 1b/2 Study Of VX15/2503 In Combination With Avelumab In Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Avelumab; MSB00100718C (Avelumab); VX15/2503
Open

CLINICAL TRIAL 19746
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors
Condition: Thoracic
Intervention: Avelumab; M3814; MSB00100718C (Avelumab)
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition: Genitourinary
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Eribulin Mesylate; NKTR-214; Nab-paclitaxel (Abraxane); Nivolumab; Paraplatin (carboplatin); Pemetrexed; Taxol (paclitaxel); carboplatin; cisplatin; paclitaxel
Open

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition: Thoracic
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib; Not Applicable; Placebo; Xalkori (Crizotinib)
Open

CLINICAL TRIAL 18999
Early Detection of Cancer Progression: Leveraging Team Science
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18871
A Phase II, Open-Label, Multicenter, Single-Arm Study To Investigate TheEfficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage Ib, Ii, Iiia Or Selected Iiib Resectable And Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18494
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 18811
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Condition: Thoracic
Intervention: ADI-PEG 20; Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Placebo; carboplatin; cisplatin
Open

CLINICAL TRIAL 19101
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); BMS-986205; Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19082
A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 19406
Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nintedanib; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17969
Randomized Study of Erlotinib vs. Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Erlotinib; Not Applicable; Placebo; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 19339
A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases
Condition: Neurologic Oncology
Intervention: AZD9291 (Osimertinib); Avastin (Bevacizumab); Bevacizumab
Open

CLINICAL TRIAL 18321
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Condition: Thoracic
Intervention: PBF-509; PDR001 (Spartalizumab)
Open

CLINICAL TRIAL 17361
A Phase I/IB Trial of MEK162 in Combination with Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Condition: Thoracic
Intervention: Erlotinib; MEK162; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 19077
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Condition: Thoracic
Intervention: Paraplatin (carboplatin); carboplatin; cisplatin; etoposide
Open

CLINICAL TRIAL 19642
A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Condition: Thoracic
Intervention: ABT-263 (Navitoclax); AZD9291 (Osimertinib); Navitoclax
Open

CLINICAL TRIAL 19163
Combination Immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC) in patients with relapsed Small Cell Lung Cancer (SCLC)
Condition: Thoracic
Intervention: Ad.p53 DC; BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19580
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3011
Open

CLINICAL TRIAL 19569
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 19619
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); G1T38; Osimertinib
Open

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable
Open

CLINICAL TRIAL 19656
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Condition: Thoracic
Intervention: Ceritinib (Zykadia); Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 19387
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Condition: Thoracic
Intervention: Poziotinib
Open

CLINICAL TRIAL 19694
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); IMC-1121B (Ramucirumab); Nivolumab; Ramucirumab
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: JNJ-61186372
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: JNJ-61186372
Open

CLINICAL TRIAL 19683
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors
Condition: Thoracic
Intervention: RMC-4630
Open

CLINICAL TRIAL 18555
A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 19491
The IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); IRX-2; Nivolumab; cyclophosphamide; cytoxan (cyclophosphamide)
Open

CLINICAL TRIAL 19757
A Phase II, Multicenter, Randomized, Two-Arm Study Of Capmatinib (INC280, An Oral MET Inhibitor) And Spartalizumab (PDR001, A PD-1 Inhibitor) Combination Therapy Versus Docetaxel In Pretreated Adult Patients With EGFR Wild-Type, ALK Rearrangement Negative Locally Advanced/Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Capmatinib; INC280 (Capmatinib); PDR001 (Spartalizumab); Spartalizumab; Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open

CLINICAL TRIAL 19685
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients with Locally Advanced Malignant Pleural Mesothelioma
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; carboplatin; cisplatin
Open

CLINICAL TRIAL 19684
A Phase I/Ib, Open-Label, Multi-Center Study of NZV930 as a Single Agent and in Combination with PDR001 and/or NIR178 in Patients with Advanced Malignancies
Condition: Thoracic
Intervention: NIR178; NZV930; PDR001 (Spartalizumab)
Open

CLINICAL TRIAL 19836
REPLATINUM: A Phase 3, Controlled, Open-label,Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma
Condition: Thoracic
Intervention: Paraplatin (carboplatin); RRx-001; carboplatin; cisplatin; etoposide
Open

CLINICAL TRIAL 19936
Maintenance Systemic Therapy versus Local Consolidative Therapy (Lct) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (Nsclc): A Randomized Phase II/III Trial
Condition: Genitourinary
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Pembrolizumab (Keytruda); Pemetrexed; Taxotere (docetaxel); docetaxel; gemcitabine
Open

CLINICAL TRIAL 19704
Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Paraplatin (carboplatin); Pemetrexed; Taxol (paclitaxel); Yervoy (Ipilimumab); carboplatin; cisplatin; etoposide; paclitaxel
Open

CLINICAL TRIAL 19820
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: INCB086550
Open

CLINICAL TRIAL 19654
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses and Treatment Intensification of a Vaccine-Based Immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for Advanced Non-Small Cell Lung Cancer and Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: AdC68; CP-675,206 (tremelimumab); PF-06801591; pDNA; tremelimumab
Open

CLINICAL TRIAL 19948
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); Cobimetinib
Open

CLINICAL TRIAL 19723
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Condition: Thoracic
Intervention: AMG 119
Open

CLINICAL TRIAL 18909
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable
Open

CLINICAL TRIAL 18398
Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Condition: Thoracic
Intervention: INC280 (Capmatinib)
Open

CLINICAL TRIAL 19940
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Plinabulin; Yervoy (Ipilimumab)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Shafique M, Tanvetyanon T. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opin Biol Ther. 2019 Mar;19(3):225-232. Pubmedid: 30657338.
  • Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res. 2018 May;10:931-940. Pubmedid: 29760563. Pmcid: PMC5937504.
  • Puri S, Shafique M, Gray JE. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. CURR TREAT OPTION ON. 2018 Jun;19(8):39. Pubmedid: 29931587.
  • Shafique MR, Lee MC, Han HS. Treatment of the Pregnant Patient with Breast Cancer. South Med J. 2017 Oct;110(10):627-631. Pubmedid: 28973702.
  • Turza KC, Shafique M, Lobo PI, Sawyer RG, Keith DS, Brayman KL, Agarwal A. Infectious complications in living-donor kidney transplant recipients undergoing multi-modal desensitization. Surg Infect (Larchmt). 2014 Jun;15(3):182-186. Pubmedid: 24773230. Pmcid: PMC4696441.
  • Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Tr. 2014 Feb;20(2):257-263. Pubmedid: 24269380. Pmcid: PMC4140655.